Biogen Completes Acquisition of Human Immunology Biosciences
Global Newswire by Notified: M&A
JULY 2, 2024
(Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bioâ„¢), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs).
Let's personalize your content